None listed
Conditions
Interventions
Drug : Selinexor 60mg PO Weekly*
Pomalidomide 4mg PO Day 1-21*
Dexamethasone Take with food 40mg PO in the a.m. Weekly
*Dosed after dialysis for patients on haemodialysis
Sponsors
Samsung Medical Center
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Previous bortezomib therapy and either • Failure to achieve at least a partial response during treatment or within 6 months of discontinuing treatment with bortezomib OR • Progressive disease during treatment or within 6 months of discontinuing treatment with bortezomib OR • Contraindication or experienced an intolerance to treatment with bortezomib 2. Previous lenalidomide therapy and either • Treatment failure with lenalidomide, as confirmed by progressive disease during treatment within 6 months of discontinuing lenalidomide • A contraindication or intolerance to treatment with lenalidomide
Exclusion criteria
Exclusion criteria: 1. Previous treatment with pomalidomide or selinexor 2. Contraindication to pomalidomide, selinexor or dexamethasone 3. Any active gastrointestinal dysfunction that prevents the patient from swallowing tablets or interferes with absorption of trial treatment. 4. Inability or unwillingness to take supportive medications such as anti-nausea and anti-anorexia agents as recommended by the National Comprehensive Cancer Network® (NCCN) Clinical Practice Guidelines in Oncology (CPGO) (NCCN CPGO) for antiemesis and anorexia/cachexia (palliative care).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS | — |
Secondary
| Measure | Time frame |
|---|---|
| Best achieved disease response on novel agent(s | — |
Countries
Korea, Republic of
Contacts
Public Contactkihyun kim
Samsung Medical Center
Outcome results
None listed